Aravax Stock

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.

Sign up today and learn more about Aravax Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Aravax Stock

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.

Funding History

December 2022$20.0M

Management

CEO

Pascal Hickey

Chief Operating Officer and Co-Founder

Sara Prickett

Co-Founder, Chief Scientific Officer

Robyn O'Hehir

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo